1626 - 1650 of 7939 Results
Title
Year
-
RESTRICTEDTitle: Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseasesJournal Name: Progress in NeurobiologyPublisher: Elsevier BVVol: 214Issue #:Start Page: 102270End Page: 102270Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.pneurobio.2022.102270Best OA location URL: https://doi.org/10.1016/j.pneurobio.2022.102270Citation Count: 89
-
RESTRICTEDTitle: An MDS Evidence‐Based Review on Treatments for Huntington's DiseaseJournal Name: Movement DisordersPublisher: WileyVol: 37Issue #: 7Start Page: 1566End Page: 1567Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.29059Citation Count: 0
-
RESTRICTEDTitle: CD11b agonists offer a novel approach for treating lupus nephritisJournal Name: Translational ResearchPublisher: Elsevier BVVol: 245Issue #:Start Page: 41End Page: 54Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.trsl.2022.03.001Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167730Citation Count: 11
-
RESTRICTEDTitle: Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease—ReplyJournal Name: JAMA NeurologyPublisher: American Medical Association (AMA)Vol: 79Issue #: 7Start Page: 726End Page: 726Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1001/jamaneurol.2022.1604Citation Count: 0
-
RESTRICTEDTitle: Convergence of signalling pathways in innate immune responses and genetic forms of Parkinson’s diseaseJournal Name: Neurobiology of DiseasePublisher: Elsevier BVVol: 169Issue #:Start Page: 105721End Page: 105721Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.nbd.2022.105721Best OA location URL: https://doi.org/10.1016/j.nbd.2022.105721Citation Count: 6
-
OPENTitle: Diabetes and Neuroaxonal Damage in Parkinson's DiseaseJournal Name: Movement DisordersPublisher: WileyVol: 37Issue #: 7Start Page: 1568End Page: 1569Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1002/mds.29067Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mds.29067Citation Count: 6
- Editor's Note2022
-
RESTRICTEDTitle: European Academy of Neurology/Movement Disorder Society‐European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive TherapiesJournal Name: Movement DisordersPublisher: WileyVol: 37Issue #: 7Start Page: 1360End Page: 1374Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/mds.29066Best OA location URL: https://digital.csic.es/bitstream/10261/306772/1/Invasive-Therapies.pdfCitation Count: 61
-
RESTRICTEDTitle: ID:16203 Brachial Plexus Stimulation for Refractory Neuropathic Upper Limb Pain in a Traumatic Brain Injury PatientJournal Name: Neuromodulation: Technology at the Neural InterfacePublisher: Elsevier BVVol: 25Issue #: 5Start Page: S6End Page: S6Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neurom.2022.02.011Citation Count: 0
-
RESTRICTEDTitle: ID:16220 Visualization Tool for DBS Programming Used With a Multiple-Source, Constant-Current System Reduces Initial Programming TimeJournal Name: Neuromodulation: Technology at the Neural InterfacePublisher: Elsevier BVVol: 25Issue #: 5Start Page: S6End Page: S7Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neurom.2022.02.012Citation Count: 0
-
RESTRICTEDTitle: Inconsistency and incongruence: the two diagnostic pillars of functional movement disorderJournal Name: The LancetPublisher: Elsevier BVVol: 400Issue #: 10348Start Page: 328End Page: 328Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s0140-6736(22)01184-9Citation Count: 7
-
RESTRICTEDTitle: Istradefylline for OFF Episodes in Parkinson’s Disease: A US Perspective of Common Clinical ScenariosJournal Name: Degenerative Neurological and Neuromuscular DiseasePublisher: Informa UK LimitedVol: Volume 12Issue #:Start Page: 97End Page: 109Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-ncDOI - Digital Object Identifier: 10.2147/dnnd.s245197Best OA location URL: https://www.dovepress.com/getfile.php?fileID=82354Citation Count: 2
-
RESTRICTEDTitle: L-Dopa response, choreic dyskinesia, and dystonia in Perry syndromeJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 100Issue #:Start Page: 19End Page: 23Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.05.023Citation Count: 5
-
OPENTitle: Loss of tau expression attenuates neurodegeneration associated with α-synucleinopathyJournal Name: Translational NeurodegenerationPublisher: Springer Science and Business Media LLCVol: 11Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1186/s40035-022-00309-xBest OA location URL: https://translationalneurodegeneration.biomedcentral.com/counter/pdf/10.1186/s40035-022-00309-xCitation Count: 9
-
RESTRICTEDTitle: LRRK2 as a target for modulating immune system responsesJournal Name: Neurobiology of DiseasePublisher: Elsevier BVVol: 169Issue #:Start Page: 105724End Page: 105724Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.nbd.2022.105724Best OA location URL: https://doi.org/10.1016/j.nbd.2022.105724Citation Count: 14
-
RESTRICTEDTitle: Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's DiseaseJournal Name: DrugsPublisher: Springer Science and Business Media LLCVol: 82Issue #: 10Start Page: 1027End Page: 1053Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s40265-022-01747-7Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40265-022-01747-7.pdfCitation Count: 9
-
RESTRICTEDTitle: Parkinson's Progression Markers Initiative brain autopsy programJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 101Issue #:Start Page: 62End Page: 65Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.06.017Citation Count: 2
-
OPENTitle: Patient Experience in Early-Stage Parkinson’s Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome AssessmentJournal Name: Neurology and TherapyPublisher: Springer Science and Business Media LLCVol: 11Issue #: 3Start Page: 1319End Page: 1340Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40120-022-00375-3Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40120-022-00375-3.pdfCitation Count: 18
-
RESTRICTEDTitle: Reply to: “Diabetes and Neuroaxonal Damage in Parkinson's Disease”Journal Name: Movement DisordersPublisher: WileyVol: 37Issue #: 7Start Page: 1569End Page: 1570Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.29064Citation Count: 0
-
OPENTitle: Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdalaJournal Name: eLifePublisher: eLife Sciences Publications, LtdVol: 11Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.7554/elife.78055Best OA location URL: https://doi.org/10.7554/elife.78055Citation Count: 15
-
RESTRICTEDTitle: The emerging role of LRRK2 in tauopathiesJournal Name: Clinical SciencePublisher: Portland Press Ltd.Vol: 136Issue #: 13Start Page: 1071End Page: 1079Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1042/cs20220067Best OA location URL: https://portlandpress.com/clinsci/article-pdf/136/13/1071/934808/cs-2022-0067.pdfCitation Count: 13
-
OPENTitle: The LRRK2 signaling network converges on a centriolar phospho-Rab10/RILPL1 complex to cause deficits in centrosome cohesion and cell polarizationJournal Name: Biology OpenPublisher: The Company of BiologistsVol: 11Issue #: 8Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1242/bio.059468Best OA location URL: https://doi.org/10.1242/bio.059468Citation Count: 14
-
OPENTitle: Characterization and diagnostic potential of R2* in early-stage progressive supranuclear palsy variantsJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 101Issue #:Start Page: 43End Page: 48Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.06.021Best OA location URL: http://www.prd-journal.com/article/S1353802022002176/pdfCitation Count: 7
-
OPENTitle: Editorial: Digital Innovation and Data-Driven Research in Neurodegenerative DiseasesJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.961847Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.961847/pdfCitation Count: 0
-
OPENTitle: Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned ratJournal Name: European Journal of PharmacologyPublisher: Elsevier BVVol: 929Issue #:Start Page: 175090End Page: 175090Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.ejphar.2022.175090Best OA location URL: https://doi.org/10.1016/j.ejphar.2022.175090Citation Count: 9